BBV154 Intranasal SARS-CoV-2 Vaccine Description
BBV154 is a replication-deficient Adenoviral vector-based (expressing a stabilized spike protein). BBV154 is an intranasal vaccine that stimulates a broad immune response – neutralizing IgG, mucosal IgA, and T cell responses.
This intranasal vaccine is non-invasive and needle-free and it is very easy to administer, not requiring trained health care workers.
India-based Bharat Biotech is a pioneering biotechnology company known for its world-class R&D and manufacturing capabilities.
BBV154 Intranasal SARS-CoV-2 Vaccine Indication
BBV154 is indicated to prevent illness caused by the SARS-CoV-2 virus. Bharat Biotech is working towards a single-dose intranasal vaccine.
Non-invasive, Needle-free, enabling ease of administration as it does not require trained health care workers.
BBV154 Intranasal SARS-CoV-2 Vaccine News
March 6, 2021 - Bharat Biotech’s intranasal COVID-19 vaccine clinical trial begins in Hyderabad.
March 4, 2021 - Approval to begin phase 1 clinical trial has been given, and the process of screening potential participants has begun.
BBV154 Intranasal SARS-CoV-2 Vaccine Clinical Trial
Clinical Trial NCT04751682: Safety and Immunogenicity of an Intranasal SARS-CoV-2 Vaccine (BBV154) for COVID-19 - Last Update Posted on February 12, 2021.
The study is designed to evaluate the safety, reactogenicity, and immunogenicity of three groups of healthy volunteers who receive either intranasal single dose (Vaccine on Day 0 and placebo on Day 28) or two-dose (vaccine on Day 0 and 28) of BBV154 vaccine or Placebo (on Day 0 and day 28). A total of 175 subjects will be enrolled in 2:2:1 ratio and will be conducted in a double-blinded manner.